United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026Business Wire • 05/17/26
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical TrialBusiness Wire • 05/15/26
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare ConferenceBusiness Wire • 05/12/26
United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026Business Wire • 05/11/26
United Therapeutics (UTHR) Misses Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/06/26
Ahead of United Therapeutics (UTHR) Q1 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks Investment Research • 05/05/26
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 05/04/26
United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of DirectorsBusiness Wire • 04/29/26
United Therapeutics (UTHR) to Report Q1 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 04/22/26
United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026Business Wire • 04/22/26
United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026Business Wire • 04/20/26
United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver FailureBusiness Wire • 04/08/26
United Therapeutics: Maintaining 'Strong Buy' On Second TETON Study Program WinSeeking Alpha • 04/01/26
UTHR Stock Rises 12.5% on Promising Data From TETON-1 Tyvaso StudyZacks Investment Research • 03/31/26
United Therapeutics (UTHR) Moves 12.5% Higher: Will This Strength Last?Zacks Investment Research • 03/31/26
United Therapeutics Tops A Buy Zone After Entering A 'New Era' With Phase 3 Home RunInvestors Business Daily • 03/30/26
United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2Business Wire • 03/30/26